The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.

Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.

The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogs.

The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogs.

Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.

The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.